Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims. RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; advisory-committee question list that exposes a weak secondary endpoint already has the discriminator after a site-change that invalidates stability claims. 2. Keep Pause the pathway in force until advisory-committee question list that exposes a weak secondary endpoint is completed after a site-change that invalidates stability claims for RWE evidence-strategy director. 3. Treat advisory-committee question list that exposes a weak secondary endpoint as Escalate safety review because both readings appear after a site-change that invalidates stability claims. 4. Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the decision to drop a secondary turns on in advisory-committee question list that exposes a weak secondary endpoint.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read advisory-committee question list that exposes a weak secondary endpoint against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (advisory-committee question list that exposes a weak secondary endpoint after a site-change that invalidates stability claims). The follow-on FDA Response and Labeling action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in advisory-committee question list that exposes a weak secondary endpoint, then the action for RWE evidence-strategy director - Hypothesis scorecard against advisory-committee question list that exposes a weak secondary endpoint: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study